华仁药业：2025年半年度公司实现营业收入623896434.45元

Group 1 - The core point of the article is that Huaren Pharmaceutical reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges for the company [1] - The company's operating revenue for the first half of 2025 was approximately 623.9 million yuan, representing a year-on-year decrease of 19.13% [1] - The net profit attributable to shareholders of the listed company was about 37.3 million yuan, showing a year-on-year decline of 49.01% [1]